s increased at higher dosages of anagrelide.
The most frequently reported adverse reactions to anagrelide (in 5% or greater of 942 patients with myeloproliferative disease) in clinical trials were:
Headache………………………….. 43.5%
Palpitations………………………… 26.1%
Diarrhea……………………………. 25.7%
Asthenia……………………………. 23.1%
Edema, other……………………… 20.6%
Nausea……………………………… 17.1%
Abdominal Pain………………….. 16.4%
Dizziness…………………………… 15.4%
Pain, other…………………………. 15.0%
Dyspnea……………………………. 11.9%
Flatulence………………………….. 10.2%
Vomiting…………………………….. 9.7%
Fever………………………………… 8.9%
Peripheral Edema………………… 8.5%
Rash, including urticaria………. 8.3%
Chest Pain…………………………. 7.8%
Anorexia……………………………. 7.7%
Tachycardia……………………….. 7.5%
Pharyngitis…………………………. 6.8%
Malaise……………………………… 6.4%
Cough……………………………….. 6.3%
Paresthesia……………………….. 5.9%
Back Pain………………………….. 5.9%
Pruritus……………………………… 5.5%
Dyspepsia…………………………. 5.2%
Adverse events with an incidence of 1% to < 5% included:
Body as a Whole System: Flu symptoms, chills, photosensitivity.
Cardiovascular System: Arrhythmia, hemorrhage, hypertension, cardiovascular disease, angina pectoris, heart failure, postural hypotension, thrombosis, vasodilatation, migraine, syncope.
Digestive System: Constipation, GI distress, GI hemorrhage, gastritis, melena, aphthous stomat |
